The Intracranial Pressure (ICP) Monitoring Market in the United States is growing due to the increasing prevalence of neurological disorders and brain injuries among patients treated in hospitals and healthcare centers. The rise in the adoption of advanced technologies and the development of non-invasive devices are driving the need for efficient ICP monitoring.
The U.S. Intracranial Pressure Monitoring Market size was USD 0.62 billion in 2025 and is forecasted to reach USD 1.16 billion by 2035, with a growth rate of 6.43% in the forecast period 2026-2035. The global market size of Intracranial Pressure Monitoring was USD 1.92 billion in 2025 and is expected to rise to USD 4.02 billion by 2035, with a growth rate of 7.68%, boosted by the preference of less invasive procedures, convenience, and application in outpatient settings.
Gain Actionable Intelligence on This Market - Request a Sample Report
U.S. Intracranial Pressure Monitoring Market Analysis
The US market is equipped with sophisticated hospital facilities, established critical care facilities, and awareness of neurological disorders. Hospitals and neurology clinics need reliable ICP monitoring devices for the treatment of patients suffering from TBI, hydrocephalus, brain tumor, and many other neurological diseases.
Technology innovations have changed the entire outlook of ICP monitoring devices in the US market. Invasive, non-invasive, wireless, portable and AI-based ICP devices are getting more popularity due to more patient-friendly approach and efficient diagnosis. The use of AI technology and analytics will help in predictive monitoring and clinical decision making.
The trend for more comfortable monitoring has also led to creation of new avenues outside hospitals. Improvements in wireless connectivity and sensor technology have facilitated continuous monitoring and increased comfort of the patient.
Top 5 Leading Intracranial Pressure Monitoring Companies
1. Medtronic plc
Medtronic is one of the largest companies dealing with medical technology and provides sophisticated solutions for neuromonitoring and ICP monitoring. The products offered by Medtronic are utilized in hospitals and critical care settings due to the company’s research and development activities, ties with health care providers, and logistical network.
2. Integra LifeSciences Holdings Corporation
Integra LifeSciences supplies neurosurgical and critical care solutions such as ICP monitors. The products are sold at hospitals and critical care centers, and the company’s dedication to the reliability of its products, along with its training services, plays a role in the widespread use of its products.
In March 2025, Integra's Codman CereLink ICP monitor is registered again in the United States, with new and improved features and improved reliability in ICP monitoring.
3. Johnson & Johnson
Johnson & Johnson is part of the neurosurgical and ICP monitoring market through its subsidiary, Codman & Shurtleff. The product line comprises monitoring solutions that are deployed in critical care and neurosurgical environments, aided by strong healthcare networks and clinical usage.
In March 2025, Codman relaunched its CereLink ICP Monitor with enhancements to regulations, accuracy, and system integration for neurosurgery.
4. Natus Medical Incorporated
Natus Medical is one of the important players in the global Intracranial Pressure Monitoring Market. Its inclusion in this group is a result of the consistent need for unique neuro-monitoring technology as hospitals increase the application of such devices.
5. Advanced Brain Monitoring, Inc.
Advanced Brain Monitoring is one of the important companies operating in the Intracranial Pressure Monitoring Market. The position held by Advanced Brain Monitoring in the competitive market scenario shows that there is a trend in the industry towards the development of advanced monitoring devices for neurological applications.
What the Future of Intracranial Pressure Monitoring Holds in the U.S.
The future of ICP monitoring in the U.S. would depend on the demand for accurate neurological assessment, increasing adoption of non-invasive technologies, and developments in AI-enabled monitoring. Hospitals and critical care units would continue to remain significant end-users of the technology, but portable devices would help the technology to get adopted in ambulatory and home care settings.
Non-invasive ICP monitoring devices would become the fastest-growing product segment in terms of demand owing to the rising demand for less invasive procedure, convenience, and adoption at outpatient centers and home care settings. The strain gauge technology would also see rapid growth owing to the growing portability, lower costs, and patient comfort. ASCs would turn out to be the fastest-growing end-user segment owing to the rising number of outpatient procedures and use of portable monitoring devices. By 2025, the adoption of ASC ICP devices would reach 50,000 units whereas the adoption of ICP devices at hospitals would be more than 280,000 units.
